Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage

Shigeki Saito, Takayuki Nakayama, Naozumi Hashimoto, Yasuhiko Miyata, Kensuke Egashira, Norihiko Nakao, Satoshi Nishiwaki, Minoru Hasegawa, Yoshinori Hasegawa, Tomoki Naoe

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Acute respiratory distress syndrome (ARDS) is a crippling disease with no effective therapy characterized by progressive dyspnea. Mesenchymal stem cells (MSCs) have emerged as a new therapeutic modality for ARDS because MSCs can attenuate inflammation and repair the damaged tissue by differentiating into several cell types. Macrophages participate in the development of ARDS; however, MSCs only weakly modulate macrophage function. The chemokine CCL2 is a potent inducer of macrophage recruitment and activation, and its expression is elevated in patients with ARDS. We established MSCs that are stably transduced by a lentiviral vector expressing 7ND, a dominant-negative inhibitor of CCL2, to enhance the therapeutic function of MSCs. 7ND-MSCs retained the innate properties of MSCs and produced a large amount of 7ND. Many 7ND-MSCs were detected in bleomycin-treated lungs (immunostaining 24 hours after injection), suggesting that MSCs could work as a drug delivery tool. Mice treated with 7ND-MSCs showed significantly milder weight loss, lung injury, collagen content, accumulation of inflammatory cells and inflammatory mediators that were induced by bleomycin, and subsequent survival benefit. No evidence of 7ND-MSCinduced toxicity was observed during or after treatment. Thus, inhibiting the effects of macrophages may greatly enhance the ability of MSCs to effect lung repair in ARDS.

Original languageEnglish
Pages (from-to)1088-1094
Number of pages7
JournalAmerican Journal of Pathology
Volume179
Issue number3
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

Bleomycin
Mesenchymal Stromal Cells
Lung
Adult Respiratory Distress Syndrome
Macrophages
Macrophage Activation
Chemokine CCL2
Lung Injury
Therapeutics
Dyspnea
Weight Loss
Collagen
Inflammation
Injections

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. / Saito, Shigeki; Nakayama, Takayuki; Hashimoto, Naozumi; Miyata, Yasuhiko; Egashira, Kensuke; Nakao, Norihiko; Nishiwaki, Satoshi; Hasegawa, Minoru; Hasegawa, Yoshinori; Naoe, Tomoki.

In: American Journal of Pathology, Vol. 179, No. 3, 01.09.2011, p. 1088-1094.

Research output: Contribution to journalArticle

Saito, S, Nakayama, T, Hashimoto, N, Miyata, Y, Egashira, K, Nakao, N, Nishiwaki, S, Hasegawa, M, Hasegawa, Y & Naoe, T 2011, 'Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage', American Journal of Pathology, vol. 179, no. 3, pp. 1088-1094. https://doi.org/10.1016/j.ajpath.2011.05.027
Saito, Shigeki ; Nakayama, Takayuki ; Hashimoto, Naozumi ; Miyata, Yasuhiko ; Egashira, Kensuke ; Nakao, Norihiko ; Nishiwaki, Satoshi ; Hasegawa, Minoru ; Hasegawa, Yoshinori ; Naoe, Tomoki. / Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. In: American Journal of Pathology. 2011 ; Vol. 179, No. 3. pp. 1088-1094.
@article{7b8cca8f17dc4ad491a6bf93b4dbca0f,
title = "Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage",
abstract = "Acute respiratory distress syndrome (ARDS) is a crippling disease with no effective therapy characterized by progressive dyspnea. Mesenchymal stem cells (MSCs) have emerged as a new therapeutic modality for ARDS because MSCs can attenuate inflammation and repair the damaged tissue by differentiating into several cell types. Macrophages participate in the development of ARDS; however, MSCs only weakly modulate macrophage function. The chemokine CCL2 is a potent inducer of macrophage recruitment and activation, and its expression is elevated in patients with ARDS. We established MSCs that are stably transduced by a lentiviral vector expressing 7ND, a dominant-negative inhibitor of CCL2, to enhance the therapeutic function of MSCs. 7ND-MSCs retained the innate properties of MSCs and produced a large amount of 7ND. Many 7ND-MSCs were detected in bleomycin-treated lungs (immunostaining 24 hours after injection), suggesting that MSCs could work as a drug delivery tool. Mice treated with 7ND-MSCs showed significantly milder weight loss, lung injury, collagen content, accumulation of inflammatory cells and inflammatory mediators that were induced by bleomycin, and subsequent survival benefit. No evidence of 7ND-MSCinduced toxicity was observed during or after treatment. Thus, inhibiting the effects of macrophages may greatly enhance the ability of MSCs to effect lung repair in ARDS.",
author = "Shigeki Saito and Takayuki Nakayama and Naozumi Hashimoto and Yasuhiko Miyata and Kensuke Egashira and Norihiko Nakao and Satoshi Nishiwaki and Minoru Hasegawa and Yoshinori Hasegawa and Tomoki Naoe",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ajpath.2011.05.027",
language = "English",
volume = "179",
pages = "1088--1094",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage

AU - Saito, Shigeki

AU - Nakayama, Takayuki

AU - Hashimoto, Naozumi

AU - Miyata, Yasuhiko

AU - Egashira, Kensuke

AU - Nakao, Norihiko

AU - Nishiwaki, Satoshi

AU - Hasegawa, Minoru

AU - Hasegawa, Yoshinori

AU - Naoe, Tomoki

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Acute respiratory distress syndrome (ARDS) is a crippling disease with no effective therapy characterized by progressive dyspnea. Mesenchymal stem cells (MSCs) have emerged as a new therapeutic modality for ARDS because MSCs can attenuate inflammation and repair the damaged tissue by differentiating into several cell types. Macrophages participate in the development of ARDS; however, MSCs only weakly modulate macrophage function. The chemokine CCL2 is a potent inducer of macrophage recruitment and activation, and its expression is elevated in patients with ARDS. We established MSCs that are stably transduced by a lentiviral vector expressing 7ND, a dominant-negative inhibitor of CCL2, to enhance the therapeutic function of MSCs. 7ND-MSCs retained the innate properties of MSCs and produced a large amount of 7ND. Many 7ND-MSCs were detected in bleomycin-treated lungs (immunostaining 24 hours after injection), suggesting that MSCs could work as a drug delivery tool. Mice treated with 7ND-MSCs showed significantly milder weight loss, lung injury, collagen content, accumulation of inflammatory cells and inflammatory mediators that were induced by bleomycin, and subsequent survival benefit. No evidence of 7ND-MSCinduced toxicity was observed during or after treatment. Thus, inhibiting the effects of macrophages may greatly enhance the ability of MSCs to effect lung repair in ARDS.

AB - Acute respiratory distress syndrome (ARDS) is a crippling disease with no effective therapy characterized by progressive dyspnea. Mesenchymal stem cells (MSCs) have emerged as a new therapeutic modality for ARDS because MSCs can attenuate inflammation and repair the damaged tissue by differentiating into several cell types. Macrophages participate in the development of ARDS; however, MSCs only weakly modulate macrophage function. The chemokine CCL2 is a potent inducer of macrophage recruitment and activation, and its expression is elevated in patients with ARDS. We established MSCs that are stably transduced by a lentiviral vector expressing 7ND, a dominant-negative inhibitor of CCL2, to enhance the therapeutic function of MSCs. 7ND-MSCs retained the innate properties of MSCs and produced a large amount of 7ND. Many 7ND-MSCs were detected in bleomycin-treated lungs (immunostaining 24 hours after injection), suggesting that MSCs could work as a drug delivery tool. Mice treated with 7ND-MSCs showed significantly milder weight loss, lung injury, collagen content, accumulation of inflammatory cells and inflammatory mediators that were induced by bleomycin, and subsequent survival benefit. No evidence of 7ND-MSCinduced toxicity was observed during or after treatment. Thus, inhibiting the effects of macrophages may greatly enhance the ability of MSCs to effect lung repair in ARDS.

UR - http://www.scopus.com/inward/record.url?scp=80052833354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052833354&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2011.05.027

DO - 10.1016/j.ajpath.2011.05.027

M3 - Article

C2 - 21741938

AN - SCOPUS:80052833354

VL - 179

SP - 1088

EP - 1094

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -